Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8132565 | 0.98 | MEN1 (0.49) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL841971 | 0.94 | BCHE (0.53) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL29381485 | 0.86 | KMT2A (0.50) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL21013099 | 0.86 | KMT2A (0.50) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL31337610 | 0.86 | STK17B (0.43) | BRD4BCHEACHESTK17BSTK17A | |
| SCHEMBL22444993 | 0.86 | BRD4 (0.45) | BRD4STK17BSTK17A | |
| SCHEMBL31709315 | 0.86 | STK17B (0.43) | BRD4BCHEACHESTK17BSTK17A | |
| SCHEMBL17675656 | 0.84 | ACHE (0.52) | GAARAB9ABCHEACHE | |
| SCHEMBL8137366 | 0.84 | BCHE (0.47) | MEN1NPC1GAARAB9AKMT2A | |
| SCHEMBL212644 | 0.84 | KMT2A (0.47) | MEN1NPC1GAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218824-A2 | IMMUNOCONJUGATE SYNTHESIS METHOD | Bolt Biotherapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3609540-B1 | IMMUNOCONJUGATE SYNTHESIS METHOD | BOLT BIOTHERAPEUTICS INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11547761-B1 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210284750-A1 | Immunoconjugate Synthesis Method | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-09-16 | — | — | US | disclosed |
| US-11110178-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200054741-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | AVIDEA TECHNOLOGIES, INC. (US) | 2020-02-20 | — | — | US | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-8143270-B2 | 2-amino 1H-in-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1784180-A4 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| EP-1784180-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006029115-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| US-6069149-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | TERUMO KABUSHIKI KAISHA (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0894797-A1 | NOVEL AMIDE DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | TERUMO KABUSHIKI KAISHA (JP) | 1999-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206357-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | MEN1 3653/4885NPC1 3603/4885GAA 3185/4885 |
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | MEN1 3653/4885NPC1 3603/4885GAA 3185/4885 |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | MEN1 3734/4885NPC1 3524/4885GAA 3205/4885 |
| US-20210284750-A1 | Immunoconjugate Synthesis Method | FCGR3B, FCGR1A, FCGR2A | MEN1 1871/4885NPC1 2378/4885GAA 2226/4885 |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | IL2, IL2RA, IL4I1 | MEN1 3048/4885NPC1 3792/4885GAA 3476/4885 |
| US-11547761-B1 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | MEN1 3653/4885NPC1 3603/4885GAA 3185/4885 |
| US-20200054741-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | MYD88, ICOS, CD4 | MEN1 3013/4885NPC1 3605/4885GAA 2950/4885 |
| US-11110178-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | MEN1 3653/4885NPC1 3603/4885GAA 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.